Combination of Glofitamab with Pirtobrutinib in BTK Inhibitor (BTKi)-Naive or Btki-Intolerant Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A Multicenter Phase 2 Study of the University of California Hematologic Malignancies ConsortiumMadhav Seshadri, Charalambos Andreadis, Monica Mead et al.|Blood|2024Cited by 1
Pembrolizumab + GVD with ctdna-guided consolidation for relapsed/refractory classic Hodgkin lymphoma: A multicenter phase 2 Study of the University of California hematologic malignancies consortiumMichael P. Randall, Michael A. Spinner, Wendy Swetzig Dhiman et al.|Blood|2025Cited by 1